Edity Therapeutics enters into a Strategic Collaboration with Dr. Reddy’s Laboratories to Advance Novel Cell Therapy Approach Using Edity’s Proprietary Delivery Platform

Edity Therapeutics announced a strategic collaboration with Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) to create novel cell therapy medicines by applying Edity’s proprietary delivery platform.

Under the agreement, Dr. Reddy’s shall provide CDMO services to Edity to support the latter’s clinical development and cell therapy manufacturing activities. Dr. Reddy’s had previously announced the acquisition of an equity stake in Edity.

Edity’s proprietary delivery platform is a powerful tool for selective tissue targeting and protein delivery. In oncology, Edity is addressing the key challenges of cell therapies in solid tumors including, antigen heterogeneity, the immunosuppressive tumor microenvironment and tumor resistance to death.

“Cell therapies have shown promise in liquid tumors, however, treating solid tumors has lagged. We believe that Edity’s technology will allow us to address the more challenging biology of solid tumors. We’ve been very impressed by Edity’s progress and are excited to work with this highly talented team,” said Erez Israeli, CEO of Dr. Reddy’s. “Edity’s approach is novel and differentiated. We look forward to the prospect of leveraging this novel first-of-its-kind platform towards solid tumors.”

“We are excited to be collaborating with Dr. Reddy’s world-class team, who have significant expertise in oncology development and cell therapy manufacturing,” said Edity CEO Michal Golan Mashiach. “This collaboration enables us to further our vision of bringing medicines with curative potential to cancer patients.”

About Dr. Reddy’s
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of ‘Good Health Can’t Wait’, we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com.

About Edity Therapeutics
Edity® Therapeutics has developed a proprietary platform for selective delivery of intracellular proteins to diseased tissues and is creating new cellular medicines with curative potential. Edity is pursuing multiple therapeutic areas and is the only company with the ability to target diseased cells with receptor-level specificity and unlock the intracellular proteome at scale. The company is developing multiple product candidates in oncology, gene therapy, autoimmunity, and regenerative medicine. Learn more at https://edity-tx.com/.

Contact Information

Abigail Bracha

President

Edity Therapeutics

abigail@edity-tx.com